Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Free Cash Flow readings, the most recent being $50.1 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow rose 124.72% to $50.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $165.7 million, a 277.1% increase, with the full-year FY2025 number at $137.9 million, up 440.03% from a year prior.
  • Free Cash Flow hit $50.1 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $54.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $62.0 million in Q3 2022 to a low of -$36.8 million in Q1 2022.
  • Median Free Cash Flow over the past 5 years was $5.2 million (2024), compared with a mean of $13.7 million.
  • Biggest five-year swings in Free Cash Flow: crashed 113.18% in 2024 and later soared 1579.43% in 2025.
  • Kiniksa Pharmaceuticals International's Free Cash Flow stood at -$11.5 million in 2022, then skyrocketed by 136.98% to $4.3 million in 2023, then soared by 338.07% to $18.7 million in 2024, then skyrocketed by 192.74% to $54.7 million in 2025, then dropped by 8.5% to $50.1 million in 2026.
  • The last three reported values for Free Cash Flow were $50.1 million (Q1 2026), $54.7 million (Q4 2025), and $33.1 million (Q3 2025) per Business Quant data.